CCR5 monoclonal antibodies for HIV-1 therapy

Current Opinion in HIV and AIDS

Volumn 4, Issue 2, 2009, Pages 104-111

  Olson, William C ^a   Jacobson, Jeffrey M ^b  

^a A Subsidiary of Lantheus Holdings   (United States)

^b DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

CCR5; HGS004; Monoclonal antibody; PRO 140

Indexed keywords

4 [(4 BROMOPHENYL)(ETHOXYIMINO)METHYL] 1' [(2,4 DIMETHYL 3 PYRIDINYL)CARBONYL] 4' METHYL 1,4' BIPIPERIDINE; ANTIVIRUS AGENT; APLAVIROC; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CCR5 MONOCLONAL ANTIBODY; DIPHENHYDRAMINE; ENFUVIRTIDE; EPITOPE; HGS 004; MARAVIROC; MONOCLONAL ANTIBODY 2D7; MONOCLONAL ANTIBODY 45523; MONOCLONAL ANTIBODY PA14; MONOCLONAL ANTIBODY ROAB13; MONOCLONAL ANTIBODY ROAB14; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; PRO 140; UNCLASSIFIED DRUG; VICRIVIROC; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; MONOCLONAL ANTIBODY; VIRUS RECEPTOR;

ANTIGEN SPECIFICITY; ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CROSS RESISTANCE; DRUG BINDING; DRUG HALF LIFE; DRUG POTENCY; DRUG POTENTIATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNITY; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN STRUCTURE; REVIEW; SINGLE DRUG DOSE; URTICARIA; VIRUS ENTRY; VIRUS LOAD; DRUG ANTAGONISM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; TREATMENT OUTCOME;

ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; HIV INFECTIONS; RECEPTORS, CCR5; RECEPTORS, HIV; TREATMENT OUTCOME; VIRAL LOAD;

EID: 65549100122     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e3283224015     Document Type: Review

References (77)

1. Lederman MM, Penn-Nicholson A, Cho M, Mosier D. Biology of CCR5 and its role in HIV infection and treatment. J Am Med Assoc 2006; 296:815-826. (Pubitemid 44223105)
2. Maddon PJ, Dalgleish AG, McDougal JS, et al. The T4 gene encodes the AIDS virus receptor and is expressed in the immune system and the brain. Cell 1986; 47:333-348.
3. Trkola A, Dragic T, Arthos J, et al. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996; 384:184-187. (Pubitemid 26386476)
4. Wu L, Gerard NP, Wyatt R, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996; 384:179-183. (Pubitemid 26386475)
5. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC- CKR-5. Nature 1996; 381:667-673. (Pubitemid 26197680)
6. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: A RANTES, MIP-1α, MIP-1β receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272:1955-1958. (Pubitemid 26234510)
7. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996; 381:661-666. (Pubitemid 26197679)
8. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane G protein-coupled receptor. Science 1996; 272:872-877. (Pubitemid 26154590)
9. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 1996; 273:1856-1862.
10. Smith MW, Dean M, Carrington M, et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science 1997; 277:959-965.
11. O'Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med 1996; 334:426-431.
12. Ioannidis JP, Rosenberg PS, Goedert JJ, et al. Effects of CCR5-Delta32, CCR2-64I, and SDF-1 3′A alleles on HIV-1 disease progression: an international meta-analysis of individual-patient data. Ann Intern Med 2001; 135:782-795.
13. van't Wout AB, Kootstra NA, Mulder-Kampinga GA, et al. Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission. J Clin Invest 1994; 94:2060-2067.
14. Moyle GJ, Petropoulos C, Goodrich J, et al. Prevalence and predictive factors for CCR5 and CXCR4 co-receptor usage in a large cohort of HIV-1 positive individuals. In: XV International AIDS Conference (Abstract WePeB5725), Bangkok, Thailand, 11-16 July 2004.
15. Seibert C, Ying W, Gavrilov S, et al. Interaction of small molecule inhibitors of HIV-1 entry with CCR5. Virology 2006; 349:41-54.
16. Cormier EG, Persuh M, Thompson DA, et al. Specific interaction of CCR5 amino-terminal domain peptides containing sulfotyrosines with HIV-1 envelope glycoprotein gp120. Proc Nat Acad Sci U S A 2000; 97:5762-5767. (Pubitemid 30367472)
17. Farzan M, Mirzabekov T, Kolchinsky P, et al. Tyrosine sulfation of the amino terminus of CCR5 facilitates HIV-1 entry. Cell 1999; 96:667-676. (Pubitemid 29122809)
18. Gonzalez E, Dhanda R, Bamshad M, et al. Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic. Proc Natl Acad Sci U S A 2001; 98:5199-5204.
19. Gonzalez E, Kulkarni H, Bolivar H, et al. The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility. Science 2005; 307:1434-1440. (Pubitemid 40321934)
20. Dolan MJ, Kulkarni H, Camargo JF, et al. CCL3L1 and CCR5 influence cell-mediated immunity and affect HIV-AIDS pathogenesis via viral entry-independent mechanisms. Nat Immunol 2007; 8:1324-1336. (Pubitemid 350131170)
21. Lim JK, Louie CY, Glaser C, et al. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 2008; 197:262-265. These studies indicate that a genetic absence of CCR5 was associated with increased risk for symptomatic and severe disease association with infection by West Nile virus and tickborne encephalitis virus. The findings illustrate a role for CCR5 in normal immune function in humans. The findings support the development of agents that preferentially block R5 HIV-1 while preserving normal CCR5 function in whole or in part. (Pubitemid 351263445)
22. Kindberg E, Mickiene A, Ax C, et al. A deletion in the chemokine receptor 5 (CCR5) gene is associated with tickborne encephalitis. J Infect Dis 2008; 197:266-269. These studies indicate that a genetic absence of CCR5 was associated with increased risk for symptomatic and severe disease association with infection by West Nile virus and tickborne encephalitis virus. The findings illustrate a role for CCR5 in normal immune function in humans. The findings support the development of agents that preferentially block R5 HIV-1 while preserving normal CCR5 function in whole or in part. (Pubitemid 351263446)
23. Wu L, Paxton W, Kassam N, et al. CCR5 levels and expression pattern correlate with infectability by macrophage-tropic HIV-1, in vitro. J Exp Med 1997; 185:1681-1691. (Pubitemid 27203264)
24. Wu L, LaRosa G, Kassam N, et al. Interaction of chemokine receptor CCR5 with its ligands: multiple domains for HIV-1 gp120 binding and a single domain for chemokine binding. J Exp Med 1997; 186:1373-1381. (Pubitemid 27469033)
25. Olson WC, Rabut GE, Nagashima KA, et al. Differential inhibition of human immunodeficiency virus type 1 fusion, gp120 binding, and CC-chemokine activity by monoclonal antibodies to CCR5. J Virol 1999; 73:4145-4155.
26. Hill CM, Kwon D, Jones M, et al. The amino terminus of human CCR5 is required for its function as a receptor for diverse human and simian immunodeficiency virus envelope glycoproteins. Virology 1998; 248:357-371. (Pubitemid 28417722)
27. Lee B, Sharron M, Blanpain C, et al. Epitope mapping of CCR5 reveals multiple conformational states and distinct but overlapping structures involved in chemokine and coreceptor function. J Biol Chem 1999; 274:9617-9626. (Pubitemid 129517938)
28. Osbourn JK, Earnshaw JC, Johnson KS, et al. Directed selection of MIP-1 alpha neutralizing CCR5 antibodies from a phage display human antibody library. Nat Biotechnol 1998; 16:778-781.
29. Rodriguez-Frade JM, Vila-Coro AJ, Martin A, et al. Similarities and differences in RANTES- and (AOP)-RANTES-triggered signals: implications for chemotaxis. J Cell Biol 1999; 144:755-765. (Pubitemid 29234553)
30. Steinberger P, Sutton JK, Rader C, et al. Generation and characterization of a recombinant human CCR5-specific antibody. A phage display approach for rabbit antibody humanization. J Biol Chem 2000; 275:36073-36078. (Pubitemid 30841153)
31. Roschke V, Clark S, Branco L, et al. Characterization of a panel of novel human monoclonal antibodies that specifically antagonize CCR5 and block HIV-1 entry. 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (Abstract 2871), Washington, DC, 30 October to 2 November 2004.
32. Ji C, Brandt M, Dioszegi M, et al. Novel CCR5 monoclonal antibodies with potent and broad-spectrum anti-HIV activities. Antiviral Res 2007; 74:125-137. The study describes the generation, antiviral properties, and antagonist activities of a novel panel of CCR5 mAbs with potent antiviral activity. The mAbs were broadly active against HIV-1 isolates from diverse genotype and against viruses that were resistant to enfuvirtide or maraviroc. (Pubitemid 46442746)
33. Blanpain C, Vanderwinden JM, Cihak J, et al. Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies. Mol Biol Cell 2002; 13:723-737. (Pubitemid 34165096)
34. Zhang J, Rao E, Dioszegi M, et al. The second extracellular loop of CCR5 contains the dominant epitopes for highly potent antihuman immunodeficiency virus monoclonal antibodies. Antimicrob Agents Chemother 2007; 51:1386-1397. Epitope specificity, affinity, and binding kinetics were determined for a panel of CCR5 mAbs with potent antiviral activity. These mAbs mapped to either the amino or carboxy portions of ECL2. The authors conclude that these regions contain the dominant epitopes for mAbs with potent anti-HIV-1 activity. (Pubitemid 46586821)
35. Doranz BJ, Lu ZH, Rucker J, et al. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J Virol 1997; 71:6305-6314. (Pubitemid 27355283)
36. Cormier EG, Dragic T. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J Virol 2002; 76:8953-8957. (Pubitemid 34864089)
37. Cormier EG, Tran DN, Yukhayeva L, et al. Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J Virol 2001; 75:5541-5549. (Pubitemid 32488147)
38. Rizzuto CD, Wyatt R, Hernandez-Ramos N, et al. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998; 280:1949-1953. (Pubitemid 28299405)
39. Rizzuto CD, Sodroski J. Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. AIDS Res Hum Retroviruses 2000; 16:741-749. (Pubitemid 30327291)
40. Huang CC, Lam SN, Acharya P, et al. Structures of the CCR5 N terminus and of a tyrosine-sulfated antibody with HIV-1 gp120 and CD4. Science 2007; 317:1930-1934. (Pubitemid 47509439)
41. Kondru R, Zhang J, Ji C, et al. Molecular interactions of CCR5 with major classes of small-molecule anti-HIV CCR5 antagonists. Mol Pharmacol 2008; 73:789-800. The authors utilize site-directed mutagenesis and dockingmodels to compare the CCR5 binding sites for five small-molecule CCR5 antagonists of clinical interest, including maraviroc and vicriviroc. The structurally diverse antagonists were proposed to fit within the same pocket formed by the transmembrane helices of CCR5. The transmembrane binding pocket for small-molecule CCR5 antagonists can be compared with the extracellular epitopes recognized by CCR5 mAbs.
42. Lalezari J, Yadavalli GK, Para M, et al. Safety, pharmacokinetics, and antiviral activity of HGS004, a novel fully human IgG4 monoclonal antibody against CCR5, in HIV-1-infected patients. J Infect Dis 2008; 197:721-727. The authors describe the results of a phase 1 study of the CCR5 mAb HGS004 in 63 participants with HIV-1 infection. The single-blind, randomized, placebo-controlled study evaluated the tolerability, pharmacokinetics, receptor occupancy, and antiviral effects of single escalating doses ranging to 40 mg/kg HGS004. The study concluded that this CCR5 mAb was generally well tolerated and demonstrated meaningful antiviral activity when administered to patients with R5 HIV-1.
43. Whitcomb JM, Huang W, Fransen S, et al. Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 2007; 51:566-575. (Pubitemid 46185274)
44. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003; 100:4144-4149. (Pubitemid 36418171)
45. Binley JM, Wrin T, Korber B, et al. Comprehensive cross-clade neutralization analysis of a panel of antihuman immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004; 78:13232-13252. (Pubitemid 39507829)
46. Olson WC, Maddon PJ. Resistance to HIV-1 entry inhibitors. Curr Drug Targets Infect Disord 2003; 3:255-262.
47. Trkola A, Ketas TJ, Nagashima KA, et al. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol 2001; 75:579-588. (Pubitemid 32037260)
48. Cilliers T, Nhlapo J, Coetzer M, et al. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol 2003; 77:4449-4456. (Pubitemid 36350986)
49. Rusert P, Kuster H, Joos B, et al. Virus Isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J Virol 2005; 79:8454-8469. (Pubitemid 40853547)
50. Shearer WT, Deville JG, Samson PM, et al. Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG(2) (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140). J Allergy Clin Immunol 2006; 118:518-521.
51. Jacobson JM, Saag MS, Thompson MA, et al. Antiviral activity of single-dose PRO 140, a CCR5 monoclonal antibody, in HIV-infected adults. J Infect Dis 2008; 198:1345-1352. The authors describe the results of a phase 1 study of the CCR5 mAb PRO 140 in 39 patients with HIV-1 infection. The randomized, double-blinded, placebo-controlled study evaluated the tolerability, pharmacokinetics, receptor occupancy, and antiviral effects of single escalating doses ranging to 5 mg/kg PRO 140. The trial established clear proof of concept for PRO 140 as a potent antiretroviral agent with extended activity after a single dose.
52. Ketas TJ, Kuhmann SE, Palmer A, et al. Cell surface expression of CCR5 and other host factors influence the inhibition of HIV-1 infection of human lymphocytes by CCR5 ligands. Virology 2007; 364:281-290. (Pubitemid 46873702)
53. Samson M, LaRosa G, Libert F, et al. The second extracellular loop of CCR5 is the major determinant of ligand specificity. J Biol Chem 1997; 272:24934-24941. (Pubitemid 27415669)
54. Dragic T, Trkola A, Lin SW, et al. Amino-terminal substitutions in the CCR5 coreceptor impair gp120 binding and human immunodeficiency virus type 1 entry. J Virol 1998; 72:279-285. (Pubitemid 28048838)
55. Vila-Coro AJ, Mellado M, Martin dA, et al. HIV-1 infection through the CCR5 receptor is blocked by receptor dimerization. Proc Natl Acad Sci U S A 2000; 97:3388-3393.
56. Murga J, Franti M, Pevear DC, et al. Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2006; 50:3289-3296. (Pubitemid 44527500)
57. Ji C, Zhang J, Dioszegi M, et al. CCR5 small-molecule antagonists and monoclonal antibodies exert potent synergistic antiviral effects by cobinding to the receptor. Mol Pharmacol 2007; 72:18-28. The study confirms and significantly extends prior studies that CCR5 mAbs synergize with small-molecule CCR5 antagonists and with other CCR5 mAbs to unrelated epitopes. Synergy between CCR5 inhibitors was attributed to cobinding of the receptor. (Pubitemid 46998521)
58. Safarian D, Carnec X, Tsamis F, et al. An anti-CCR5 monoclonal antibody and small molecule CCR5 antagonists synergize by inhibiting different stages of human immunodeficiency virus type 1 entry. Virology 2006; 352:477-484. (Pubitemid 44216012)
59. Trkola A, Kuhmann SE, Strizki JM, et al. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci U S A 2002; 99:395-400.
60. Marozsan AJ, Kuhmann SE, Morgan T, et al. Generation and properties of a human immunodeficiency virus type 1 isolate resistant to the small molecule CCR5 inhibitor, SCH-417690 (SCH-D). Virology 2005; 338: 182-199. (Pubitemid 40835936)
61. Kuhmann SE, Pugach P, Kunstman KJ, et al.Genetic and phenotypic analyses of human immunodeficiency virus type 1 escape from a small-molecule CCR5 inhibitor. J Virol 2004; 78:2790-2807. (Pubitemid 38314338)
62. Westby M, Smith-Burchnell C, Mori J, et al. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J Virol 2007; 81:2359-2371. (Pubitemid 46303353)
63. Ogert RA, Wojcik L, Buontempo C, et al. Mapping resistance to the CCR5 coreceptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120. Virology 2008; 373:387-399.
64. Pugach P, Marozsan AJ, Ketas TJ, et al. HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry. Virology 2007; 361:212-228. This study describes the phenotypes of viruses selected in vitro for resistance to vicriviroc and AD101, a chemically related compound. Each escape mutant virus was observed to be cross-resistant to maraviroc, aplaviroc, and other small-molecule CCR5 antagonists when assayed in cultures of primary CD4+ T cells. However, the escape mutant viruses remained susceptible to inhibition by mAb PRO 140. The findings extend prior studies that reported different resistance profiles for mAb and small-molecule inhibitors of CCR5. (Pubitemid 46551222)
65. Westby M, Lewis M, Whitcomb J, et al. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80:4909-4920.
66. Tsibris AM, Sagar M, Gulick RM, et al. In vivo emergence of vicriviroc resistance in a human immunodeficiency virus type 1 subtype C-infected subject. J Virol 2008; 82:8210-8214. This study characterized the genotypes and phenotypes of viruses isolated from a patient following failure of a vicriviroc-containing regimen. The isolates exhibited high-level resistance to vicriviroc, cross-resistance to another small-molecule CCR5 antagonist, and increased susceptibility to inhibition of the CCR5 mAb HGS004. The findings for these clinical isolates complement similar findings reported previously for viruses selected in vitro for resistance to small-molecule antagonists.
67. Watson C, Jenkinson S, Kazmierski W, Kenakin T. The CCR5 receptor-based mechanism of action of 873140, a potent allosteric noncompetitive HIV entry inhibitor. Mol Pharmacol 2005; 67:1268-1282. (Pubitemid 40410427)
68. Kenakin T. How pharmacological receptor theory can guide new drug discovery CCR5 HIV inhibitors in AIDS as a case study. Proc West Pharmacol Soc 2007; 50:1-7.
69. Haworth B, Lin H, Fidock M, et al. Allosteric effects of antagonists on signalling by the chemokine receptor CCR5. Biochem Pharmacol 2007; 74:891-897. (Pubitemid 47212080)
70. Pugach P, Ketas TJ, Michael E, Moore JP. Neutralizing antibody and antiretroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors. Virology 2008; 377:401-407.
71. Chan PL, Weatherley B, McFadyen L. A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects. Br J Clin Pharmacol 2008; 65 (Suppl 1):76-85.
72. Adkison KK, Shachoy-Clark A, Fang L, et al. Pharmacokinetics and short-term safety of 873140, a novel CCR5 antagonist, in healthy adult subjects. Antimicrob Agents Chemother 2005; 49:2802-2806. (Pubitemid 40917594)
73. Johnson BM, Song IH, Adkison KK, et al. Evaluation of the drug interaction potential of aplaviroc,anovelhumanimmunodeficiencyvirusentry inhibitor,using a modified cooperstown 5 + 1 cocktail. J Clin Pharmacol 2006; 46:577-587.
74. Ketas TJ, Frank I, Klasse PJ, et al. Human immunodeficiency virus type 1 attachment, coreceptor and fusion inhibitors are active against both direct and trans infection of primary cells. J Virol 2003; 77:2762-2767. (Pubitemid 36222803)
75. Fatkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005; 11:1170-1172. (Pubitemid 43093663)
76. Lalezari J, Thompson M, Kumar P, et al. 873140, a novel CCR5 antagonist: Antiviral activity and safety during short-term monotherapy in HIV-infected adults. 44th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (Abstract 2871), Washington, DC, 30 October to 2 November 2004.
77. Schurmann D, Fatkenheuer G, Reynes J, et al. Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults. AIDS 2007; 21:1293-1299. (Pubitemid 46883483)